The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Pharmacia & Upjohn
Approval Status: Approved October 1998
Treatment for: Oncology
General Information
Treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy.
Side Effects
The adverse effects of Camptosar, such as myelosuppression and diarrhea, would be expected to be exacerbated by other antineoplastic agents having similar adverse effects.
Other potential side effects include diarrhea, neutropenia among others.
